{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T22:33:37Z","timestamp":1766788417497},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T00:00:00Z","timestamp":1434931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National R&D Program for Cancer Control","award":["1320090"],"award-info":[{"award-number":["1320090"]}]},{"name":"Ministry of Health and Welfare of the Republic of Korea"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>In advanced biliary tract cancer (BTC), the metabolic landscape has not been evaluated by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) yet. Furthermore, reports of the clinical implications of these metabolic features are limited. We aimed to evaluate the metabolic features and their clinical relevance in advanced BTC using 18F-FDG PET.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods.<\/jats:title>\n                  <jats:p>We consecutively enrolled patients with advanced BTC who underwent 18F-FDG PET prior to palliative chemotherapy between 2003 and 2013. We evaluated the findings of PET, such as SUVmax, the number of lesions and organs with FDG uptake, pathologic findings, and clinical outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>A total of 106 patients were enrolled: (53 intrahepatic cholangiocarcinoma [ICC], 7 extrahepatic BTC, 30 gallbladder cancer [GB Ca], and 16 ampulla of Vater cancer [AoV Ca]). The median SUVmax differed according to the primary origin (ICC, 9.10; extrahepatic BTC, 5.90; GB Ca, 9.10; and AoV Ca, 6.37; p = .008) and histologic differentiation (well differentiated, 4.95; moderately differentiated, 6.60; poorly differentiated, 14.50; p = .004). Patients in the high metabolic group (SUVmax of \u22657.5) had more poorly differentiated histology and more organs and lesions with FDG uptake than did those in the low metabolic group (SUVmax of &amp;lt;7.5). The low metabolic group had a significantly longer OS (11.4 vs. 7.4 months, p = .007) and PFS (6.6 vs. 4.3 months, p = .024) than high metabolic group. In multivariate analysis, SUVmax was a significant prognostic factor for overall survival (OS; p = .047) and progression-free survival (PFS; p = .039).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Metabolic characteristics of advanced BTC differ according to primary origin and histology. These metabolic features could be prognostic factors for OS and PFS in advanced BTC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice:<\/jats:title>\n                  <jats:p>The metabolic landscape of advanced biliary tract cancer and its clinical meanings have not yet been comprehensively studied. This study shows that metabolic characteristics of advanced biliary tract cancer differ significantly according to primary origin and histology. Moreover, this metabolic activity is associated with patients\u2019 outcomes, including overall survival and progression-free survival. This study supports tumor heterogeneity in terms of cancer metabolism in biliary tract cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2014-0356","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T01:21:10Z","timestamp":1435022470000},"page":"926-933","source":"Crossref","is-referenced-by-count":13,"title":["Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications"],"prefix":"10.1093","volume":"20","author":[{"given":"Kyoung-Min","family":"Cho","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea;"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Yong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea;"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Hun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea;"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae-Won","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea;"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea;"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-You","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea;"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Jue","family":"Bang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea;"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,6,22]]},"reference":[{"key":"2021122309364347200_B1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"2021122309364347200_B2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4143\/crt.2004.36.2.103","article-title":"2002 annual report of the Korea Central Cancer Registry: Based on registered data from 139 hospitals","volume":"36","author":"Shin","year":"2004","journal-title":"Cancer Res Treat"},{"key":"2021122309364347200_B3","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJM199910283411807","article-title":"Biliary tract cancers","volume":"341","author":"De Groen","year":"1999","journal-title":"N Engl J Med"},{"key":"2021122309364347200_B4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00428-006-0255-9","article-title":"COX-2 expression of ampullary carcinoma: Correlation with different histotypes and clinicopathological parameters","volume":"449","author":"Perrone","year":"2006","journal-title":"Virchows Arch"},{"key":"2021122309364347200_B5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/PAS.0b013e3181983ef7","article-title":"Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions","volume":"33","author":"Ruemmele","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"2021122309364347200_B6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s00330-013-3037-1","article-title":"18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes","volume":"24","author":"Koo","year":"2014","journal-title":"Eur Radiol"},{"key":"2021122309364347200_B7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/IGC.0b013e3181c3a288","article-title":"The SUVmax of 18F-FDG PET correlates with histological grade in endometrial cancer","volume":"20","author":"Nakamura","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"2021122309364347200_B8","first-page":"437","article-title":"Expression of facilitative glucose transporter isoforms in lung carcinomas: Its relation to histologic type, differentiation grade, and tumor stage","volume":"11","author":"Ito","year":"1998","journal-title":"Mod Pathol"},{"key":"2021122309364347200_B9","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.ijrobp.2003.12.039","article-title":"Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose","volume":"59","author":"Allal","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309364347200_B10","first-page":"958","article-title":"Letter: Expression of tissue isotope distribution","volume":"16","author":"Woodard","year":"1975","journal-title":"J Nucl Med"},{"key":"2021122309364347200_B11","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ejcts.2008.07.023","article-title":"Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: Analysis of 176 cases","volume":"34","author":"Al-Sarraf","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"2021122309364347200_B12","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1200\/JCO.2004.11.109","article-title":"Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection","volume":"22","author":"Downey","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122309364347200_B13","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00259-012-2164-2","article-title":"Role of \u00b9\u2078F-FDG PET\/CT in the prediction of gastric cancer recurrence after curative surgical resection","volume":"39","author":"Lee","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021122309364347200_B14","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2005.06.129","article-title":"[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer","volume":"23","author":"Sasaki","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122309364347200_B15","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s00259-011-2057-9","article-title":"Prognostic significance of SUVmax (maximum standardized uptake value) measured by [\u00b9\u2078F]FDG PET\/CT in endometrial cancer","volume":"39","author":"Kitajima","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021122309364347200_B16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2009.06.022","article-title":"The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: Preliminary results","volume":"115","author":"Lee","year":"2009","journal-title":"Gynecol Oncol"},{"key":"2021122309364347200_B17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1186\/1471-2407-10-667","article-title":"Impact of maximum standardized uptake value (SUVmax) evaluated by 18-fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography (18F-FDG-PET\/CT) on survival for patients with advanced renal cell carcinoma: A preliminary report","volume":"10","author":"Namura","year":"2010","journal-title":"BMC Cancer"},{"key":"2021122309364347200_B18","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/MEG.0b013e328323d6fa","article-title":"Prognostic significance of SUV on PET\/CT in patients with esophageal cancer: A systematic review and meta-analysis","volume":"21","author":"Pan","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2021122309364347200_B19","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/jso.21356","article-title":"Prognostic importance of standardized uptake value on F-18 fluorodeoxyglucose-positron emission tomography in biliary tract carcinoma","volume":"100","author":"Furukawa","year":"2009","journal-title":"J Surg Oncol"},{"key":"2021122309364347200_B20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00534-010-0293-1","article-title":"Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer","volume":"18","author":"Kitamura","year":"2011","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2021122309364347200_B21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia: A key regulatory factor in tumour growth","volume":"2","author":"Harris","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2021122309364347200_B22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/jso.23476","article-title":"Ability of FDG-PET\/CT in the detection of gallbladder cancer","volume":"109","author":"Ramos-Font","year":"2014","journal-title":"J Surg Oncol"},{"key":"2021122309364347200_B23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtcvs.2004.11.007","article-title":"The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival","volume":"130","author":"Cerfolio","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2021122309364347200_B24","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.ejca.2007.03.027","article-title":"The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer","volume":"43","author":"Van Baardwijk","year":"2007","journal-title":"Eur J Cancer"},{"key":"2021122309364347200_B25","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1158\/1078-0432.CCR-06-1128","article-title":"Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: New contrary data on prognostic role","volume":"13","author":"Vesselle","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122309364347200_B26","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/00006231-200209000-00010","article-title":"Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer","volume":"23","author":"Jeong","year":"2002","journal-title":"Nucl Med Commun"},{"key":"2021122309364347200_B27","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00259-006-0224-1","article-title":"Quantification of FDG PET studies using standardised uptake values in multi-centre trials: Effects of image reconstruction, resolution and ROI definition parameters","volume":"34","author":"Westerterp","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021122309364347200_B28","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa","year":"2008","journal-title":"Br J Cancer"},{"key":"2021122309364347200_B29","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/path.1779","article-title":"Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers","volume":"206","author":"Nakazawa","year":"2005","journal-title":"J Pathol"},{"key":"2021122309364347200_B30","first-page":"1051","article-title":"Clinical significance of hepatocyte growth factor and c-Met expression in extrahepatic biliary tract cancers","volume":"6","author":"Hida","year":"1999","journal-title":"Oncol Rep"},{"key":"2021122309364347200_B31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s13304-013-0205-4","article-title":"Sensitivity and specificity of FDG PET-CT scan in detecting lymph node metastasis in operable periampullary tumours in correlation with the final histopathology after curative surgery","volume":"65","author":"Raj","year":"2013","journal-title":"Updates Surg"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2014-0356","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2014-0356","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/8\/926\/41870135\/oncolo_20_8_926.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/8\/926\/41870135\/oncolo_20_8_926.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T03:37:50Z","timestamp":1640317070000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/8\/926\/6399660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,22]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,6,22]]},"published-print":{"date-parts":[[2015,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2014-0356","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,8,1]]},"published":{"date-parts":[[2015,6,22]]}}}